摘要 : This update covers an important, yet small portion of the COPD research published during 2016. Advances have been made regarding how we should use existing therapies, both by identifying recipients who might benefit most and deter... 展开 This update covers an important, yet small portion of the COPD research published during 2016. Advances have been made regarding how we should use existing therapies, both by identifying recipients who might benefit most and determining how the benefits acquired from therapies might be optimized. The studies discussed also highlight opportunities to tailor COPD therapy to an individual patient by considering their clinical phenotype, the nature of their airway inflammation, and their comorbidities. In addition, the approach by which therapy is delivered can also be personalized to help the individual optimally manage their long-term condition. Although smoking cessation and avoidance remain central to COPD prevention and progression, the lack of therapies capable of modifying established disease remains frustrating. Perhaps by better understanding the mechanisms by which COPD develops and how disease heterogeneity evolves across life we might discover those game-changing therapeutic approaches that have thus far remained elusive. 收起